Opioid-Related Adverse Events: Incidence and Impact in Patients Undergoing Cardiac Surgery

2019 ◽  
Vol 24 (3) ◽  
pp. 219-226 ◽  
Author(s):  
Keith B. Allen ◽  
Ethan Y. Brovman ◽  
Adnan K. Chhatriwalla ◽  
Katherine J. Greco ◽  
Nikhilesh Rao ◽  
...  

Purpose. Opioid-related adverse drug events (ORADEs) increase patient length of stay (LOS) and health care costs. However, ORADE rates may be underreported. This study attempts to understand the degree to which ORADEs are underreported in Medicare patients undergoing cardiac surgery. Materials and Methods. The Center for Medicare and Medicaid Services administrative claims database was used to identify ORADEs in 110 158 Medicare beneficiaries who underwent cardiac valve (n = 50 525) or coronary bypass (n = 59 633) surgery between April 2016 and March 2017. The International Classification of Disease (ICD)-10 codes specifically linked to ORADEs were used to identify an actual ORADE rate, while additional ICD codes, clinically associated with butas not specific to adverse drug events were analyzed as potential ORADEs. Length of stay (LOS) and hospital daily revenue were analyzed among patients with or without a potential ORADE. Results. Among patients undergoing valve or bypass surgery, the documented ORADE rate was 0.7% (743/110 158). However, potential ORADEs may have occurred in up to 32.4% (35 658/110 158) of patients. In patients with a potential ORADE, mean LOS was longer (11.4 vs 8.2 days; P < .0001) and mean Medicare revenue/day was lower ($4016 vs $4412; P < .0001). The mean net difference in revenue/day between patients with and without an ORADE varied between $231 and $1145, depending on the Diagnosis-Related Group analyzed. Conclusions. ORADEs are likely underreported following cardiac surgery. ORADEs can be associated with increased LOS and decreased hospital revenue. Understanding the incidence and economic impact of ORADEs may expedite changes to postoperative pain management. Adopting multimodal pain management strategies that reduce exposure to opioids may improve outcomes by reducing complications, side effects, and health care costs.

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Sarah-Gabrielle Beland ◽  
Antoine Pariente ◽  
Yola Moride

Background. Published data on burden of dementia mainly include patients of third-care facilities. Economic consequences in an outpatient setting remain poorly examined. Objectives. To evaluate institutionalization-free survival and direct health care costs of dementia in the Quebec community-dwelling elderly population. Methods. A retrospective cohort study was conducted using the Quebec administrative claims databases. The cohort included a random sample of patients with treated dementia between January 1, 2000, and December 31, 2009 (n=37,138). The reference population included elderly patients without dementia matched in age group, gender, and index date. Using a third-party payer perspective, direct costs over 5 years were assessed. Results. Institutionalization-free survival at 5 years was lower in patients with dementia than in elderly without dementia (38.9% and 72.2%, resp.). Over 5 years, difference in mean total direct health care costs per patient was CAD$19,159, distributed into institutionalizations (CAD$13,598), hospitalizations (CAD$3,312), and prescribed medications (CAD$2,320). Costs of medical services were similar (−CAD$96). In the first year of followup, cost differentials were mainly attributable to hospitalizations, while in the last year (year 5) they were due to institutionalizations. Conclusion. This study confirms that dementia is an important socioeconomic burden in the community, the nature of which depends on disease progression.


2014 ◽  
Vol 33 ◽  
pp. S73
Author(s):  
S. Klek ◽  
A. Hermanowicz ◽  
G. Dziwiszek ◽  
K. Matysiak ◽  
K. Szczepanek ◽  
...  

2011 ◽  
Vol 21 (1) ◽  
pp. 44-60 ◽  
Author(s):  
Jin-Hee Chang ◽  
Kyoung-Hoon Kim ◽  
Soon-Man Kwon ◽  
Seon-A Yeom ◽  
Choon-Seon Park

2006 ◽  
Vol 14 (7S_Part_28) ◽  
pp. P1501-P1502
Author(s):  
Rezaul Karim Khandker ◽  
Richard B. Lipton ◽  
Ellen Thiel ◽  
Matthew Brouillette ◽  
Christopher M. Black

2014 ◽  
Vol 33 ◽  
pp. S70
Author(s):  
S. Klek ◽  
A. Hermanowicz ◽  
G. Dziwiszek ◽  
K. Szczepanek ◽  
P. Szybinski ◽  
...  

2018 ◽  
Vol 1 (1) ◽  
pp. 120-128 ◽  
Author(s):  
Shota Saito ◽  
Kyoko Nakazawa ◽  
Kenji Suzuki ◽  
Takashi Ishikawa ◽  
Kouhei Akazawa

Anti-tumor necrosis factor-α (anti-TNFα) agents are used for induction and maintenance of remission in patients with inflammatory bowel diseases (IBD). However, biologic drugs present a large economic burden on health insurance systems. We aimed to estimate the mean annual health care cost per patient with IBD and cost contribution of anti-TNFα agents. We performed an analysis of patients with Crohn’s disease (CD) and ulcerative colitis (UC) based on a large-scale administrative claims database constructed by Japan Medical Data Center (JMDC) Co. Ltd., comprising inpatient, outpatient, and pharmacy claims data. We evaluated all claims from 1 April 2013 through 31 March 2016. Descriptive statistics were used to measure median health care costs paid per member per year (PMPY) and the relative cost contribution of anti-TNFα agents. A total 1405 patients with CD and 5771 with UC were included. Median costs PMPY were approximately six times higher for CD than UC (JPY 1,957,320 and JPY 278,760, respectively). Medication cost for anti-TNFα agents was the main cost driver, accounting for 59.9% and 17.8% of the total costs for CD and UC, respectively. In Japan, costs for anti-TNFα agents have resulted in drug costs exceeding inpatient costs for IBD. Optimized use of anti-TNFα agents and introduction of biosimilars for anti-TNFα agents can be expected to substantially reduce the health care costs of IBD.


2014 ◽  
Vol 186 (2) ◽  
pp. 608-609
Author(s):  
P.R. Fillmore ◽  
B. Armstrong ◽  
M. Johnson ◽  
S. Tsuda ◽  
T. Browder ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document